Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Amova Asset Management Americas Inc.

Amova Asset Management Americas Inc. lessened its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 13.3% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 20,224 shares of the biopharmaceutical company’s stock after selling 3,090 shares during the quarter. Amova Asset Management Americas Inc.’s holdings in Regeneron Pharmaceuticals were worth $11,371,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in REGN. Osaic Holdings Inc. lifted its position in shares of Regeneron Pharmaceuticals by 55.2% in the second quarter. Osaic Holdings Inc. now owns 17,068 shares of the biopharmaceutical company’s stock valued at $9,607,000 after acquiring an additional 6,073 shares in the last quarter. Robeco Institutional Asset Management B.V. raised its stake in Regeneron Pharmaceuticals by 153.4% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 120,884 shares of the biopharmaceutical company’s stock valued at $67,969,000 after purchasing an additional 73,176 shares during the last quarter. PGGM Investments lifted its holdings in Regeneron Pharmaceuticals by 9.7% in the 3rd quarter. PGGM Investments now owns 92,584 shares of the biopharmaceutical company’s stock valued at $52,057,000 after purchasing an additional 8,187 shares in the last quarter. Rakuten Investment Management Inc. acquired a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter worth about $33,121,000. Finally, Sound Shore Management Inc CT purchased a new stake in shares of Regeneron Pharmaceuticals during the third quarter worth about $64,677,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ:REGN opened at $787.50 on Thursday. The business has a 50-day moving average of $771.61 and a two-hundred day moving average of $686.10. The firm has a market capitalization of $83.25 billion, a PE ratio of 18.95, a P/E/G ratio of 2.06 and a beta of 0.41. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.13 and a quick ratio of 3.39. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.74 by $0.70. The business had revenue of $3.88 billion during the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The company’s revenue for the quarter was up 2.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $12.07 EPS. As a group, research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 5th. Stockholders of record on Friday, February 20th will be given a $0.94 dividend. The ex-dividend date of this dividend is Friday, February 20th. This is an increase from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 9.05%.

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, Director Bonnie L. Bassler sold 1,500 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the transaction, the director owned 1,703 shares in the company, valued at approximately $1,362,400. The trade was a 46.83% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Jason Pitofsky sold 2,036 shares of the company’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the sale, the senior vice president directly owned 4,272 shares of the company’s stock, valued at approximately $3,325,837.44. This trade represents a 32.28% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 5,274 shares of company stock worth $4,142,738. 7.02% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on REGN. Cantor Fitzgerald upped their price objective on shares of Regeneron Pharmaceuticals from $740.00 to $800.00 and gave the company an “overweight” rating in a research note on Monday, February 2nd. Guggenheim increased their price target on Regeneron Pharmaceuticals from $865.00 to $975.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. JPMorgan Chase & Co. raised their price objective on Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the stock an “overweight” rating in a report on Monday, February 2nd. Weiss Ratings reiterated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Monday, December 29th. Finally, Morgan Stanley increased their target price on Regeneron Pharmaceuticals from $768.00 to $769.00 and gave the stock an “equal weight” rating in a research report on Monday, February 2nd. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $796.52.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.